LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2
文献类型：期刊论文
| 作者 | Yu, Hua2,5; Ding, Jun1; Zhu, Hongwen3,4; Jing, Yao1; Zhou, Hu3,4 ; Tian, Hengli1; Tang, Ke2; Wang, Gang2; Wang, Xiongjun2,5
|
| 刊名 | CELL DEATH AND DIFFERENTIATION
 |
| 出版日期 | 2020-05-18 |
| 页码 | 16 |
| ISSN号 | 1350-9047 |
| DOI | 10.1038/s41418-020-0558-4 |
| 通讯作者 | Wang, Xiongjun(xjwang02@sibcb.ac.cn) |
| 英文摘要 | The lysyl oxidase (LOX) family is closely related to the progression of glioma. To ensure the clinical significance of LOX family in glioma, The Cancer Genome Atlas (TCGA) database was mined and the analysis indicated that higher LOXL1 expression was correlated with more malignant glioma progression. The functions of LOXL1 in promoting glioma cell survival and inhibiting apoptosis were studied by gain- and loss-of-function experiments in cells and animals. LOXL1 was found to exhibit antiapoptotic activity by interacting with multiple antiapoptosis modulators, especially BAG family molecular chaperone regulator 2 (BAG2). LOXL1-D515 interacted with BAG2-K186 through a hydrogen bond, and its lysyl oxidase activity prevented BAG2 degradation by competing with K186 ubiquitylation. Then, we discovered that LOXL1 expression was specifically upregulated through the VEGFR-Src-CEBPA axis. Clinically, the patients with higher LOXL1 levels in their blood had much more abundant BAG2 protein levels in glioma tissues. Conclusively, LOXL1 functions as an important mediator that increases the antiapoptotic capacity of tumor cells, and approaches targeting LOXL1 represent a potential strategy for treating glioma. In addition, blood LOXL1 levels can be used as a biomarker to monitor glioma progression. |
| WOS关键词 | LYSYL OXIDASE LOX ; TUMOR-SUPPRESSOR ACTIVITY ; CANCER ; PROTEIN ; IDENTIFICATION ; SPECIFICITY ; ACTIVATION ; RESISTANCE ; PHENOTYPE ; APOPTOSIS |
| 资助项目 | Hundred Talent Program of Guangzhou University ; National Natural Science Foundation of China[31671508] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Cell Biology |
| 语种 | 英语 |
| 出版者 | NATURE PUBLISHING GROUP |
| WOS记录号 | WOS:000533832400003 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/280310]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Xiongjun |
| 作者单位 | 1.Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Neurosurg, 600 Yishan Rd, Shanghai 200233, Peoples R China 2.Guangzhou Univ, Precise Genome Engn Ctr, Sch Life Sci, Guangzhou 510006, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Analyt Chem, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China 5.Chinese Acad Sci, Univ Chinese Acad Sci, Inst Hlth Sci, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yu, Hua,Ding, Jun,Zhu, Hongwen,et al. LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2[J]. CELL DEATH AND DIFFERENTIATION,2020:16. |
| APA | Yu, Hua.,Ding, Jun.,Zhu, Hongwen.,Jing, Yao.,Zhou, Hu.,...&Wang, Xiongjun.(2020).LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2.CELL DEATH AND DIFFERENTIATION,16. |
| MLA | Yu, Hua,et al."LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2".CELL DEATH AND DIFFERENTIATION (2020):16. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。